Pharnext SCA
OTC:PNEXF

Watchlist Manager
Pharnext SCA Logo
Pharnext SCA
OTC:PNEXF
Watchlist
Price: 999 999.9999 USD
Market Cap: 6T USD
Have any thoughts about
Pharnext SCA?
Write Note

Pharnext SCA
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pharnext SCA
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Pharnext SCA
OTC:PNEXF
Cash from Investing Activities
€490k
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Cash from Investing Activities
€55.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Cash from Investing Activities
-€1.1m
CAGR 3-Years
N/A
CAGR 5-Years
18%
CAGR 10-Years
-7%
Inventiva SA
PAR:IVA
Cash from Investing Activities
€8.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Cash from Investing Activities
-€318k
CAGR 3-Years
58%
CAGR 5-Years
29%
CAGR 10-Years
-5%
OSE Immunotherapeutics SA
PAR:OSE
Cash from Investing Activities
-€55.5m
CAGR 3-Years
N/A
CAGR 5-Years
-160%
CAGR 10-Years
N/A
No Stocks Found

Pharnext SCA
Glance View

Market Cap
6T USD
Industry
Biotechnology

Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.

PNEXF Intrinsic Value
Not Available

See Also

What is Pharnext SCA's Cash from Investing Activities?
Cash from Investing Activities
490k EUR

Based on the financial report for Jun 30, 2023, Pharnext SCA's Cash from Investing Activities amounts to 490k EUR.

What is Pharnext SCA's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
10%

Over the last year, the Cash from Investing Activities growth was 308%. The average annual Cash from Investing Activities growth rates for Pharnext SCA have been 10% over the past three years .

Back to Top